Preliminary study shows high-dose coenzyme Q10 slows functional decline in Parkinson's patients

A national clinical trial with 80 Parkinson's disease patients has shown that high dosages of a naturally occurring compound, coenzyme Q10, slowed by 44 percent the progressive deterioration in function that occurs in the disease. The greatest benefit was seen in everyday activities such as feeding, dressing, bathing and walking.

The study's coordinators caution that while encouraging, the therapy needs to be tested in a larger trial with hundreds of patients before this treatment can be recommended.

Published in the Oct. 15, 2002 issue of the American Medical Association's Archives of Neurology, the study was conducted at 10 sites by the Parkinson Study Group, under the direction of principal investigator Clifford Shults, M.D., professor of neurosciences, University of California, San Diego (UCSD) School of Medicine, and chief of the Neurology Service at the VA San Diego Healthcare System. Parkinson's disease is a degenerative disorder of the brain in which patients develop tremor, slowness of movement and stiffness of muscles. It affects approximately 1 percent of Americans over the age of 65. Although certain drugs, such as levodopa, can reduce the symptoms of Parkinson's disease, no treatment has been shown to slow the progressive deterioration in function.

The selection of coenzyme Q10 as a potential treatment for Parkinson's was based on work carried out over the past decade by Shults, Richard Haas, M.D., UCSD professor of neurosciences, and Flint Beal, M.D., professor and chair of neurology, Weill Medical College of Cornell University.

Shults explained that mitochondria produce the energy-containing molecules that supply energy to chemical reactions in cells and that coenzyme Q10 plays an integral role in that process. He further explained that coenzyme Q10 is also a potent antioxidant. Over the past several years, research by Shults, Haas and Beal showed that mitochondrial function is impaired in patients with Park

Contact: Sue Pondrom
University of California - San Diego

Page: 1 2 3 4

Related medicine news :

1. Preliminary results are promising in Alzheimers gene therapy trial
2. Preliminary report suggests combination therapy may help treat SARS
3. Preliminary study finds stem cells in blood restore damaged heart muscle
4. Preliminary study suggests endomitriosis could contribute to infertility
5. Preliminary US study findings support excellent results with CYPHER Sirolimus-eluting Stent
6. Preliminary Study Proves Centuries Of Herbalists Right About Echinacea
7. ACTG 315 Preliminary Results: Drug Cocktail Restores Partial Immune Function
8. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
9. UMaine study looks at infants and chronic nighttime crying
10. Chronic pain treatments more effective when taken together, new study shows
11. UNC study: Most N.C. family practitioners engage in unrecognized community service

Post Your Comments:
(Date:10/8/2015)... (PRWEB) , ... October 08, 2015 , ... Multicultural competencies ... Day, presented by Calvary Hospital. , The ninth annual event will take place from ... on Second Avenue at 34th Street in Manhattan. This location was chosen to conveniently ...
(Date:10/8/2015)... ... October 08, 2015 , ... In an increasingly complex healthcare ... to consistently deliver the highest quality of care, while exploring controversial issues impacting ... this year’s NASS meeting, the Spine division of Zimmer Biomet, a leading global ...
(Date:10/8/2015)... ... October 08, 2015 , ... Mirixa Corporation ... decade as the recognized leader in targeted patient care services, Mirixa remains dedicated ... community pharmacies available. Recent changes in the health care marketplace threaten to limit ...
(Date:10/8/2015)... White Plains, NY (PRWEB) , ... October 08, 2015 , ... ... comparison company, shows that popular, branded maintenance medications can be purchased at an 84% ... The greatest savings is 94% for the acid-blocking drug Nexium ($946.50 in the U.S. ...
(Date:10/8/2015)... ... 08, 2015 , ... Carpet One Floor & Home has just released their ... One Welcomes Your Support campaign has been raising funds to support organizations and researchers ... , Twenty-five percent of each sale will be donated to the Breast Cancer ...
Breaking Medicine News(10 mins):
(Date:10/8/2015)...  Clariant, a world leader in specialty chemicals, has announced ... Belen, New Mexico , has achieved ISO 15378:2011 ... canisters and packets and other container-closure systems . ... second Clariant site – the first in the ... standards, following only the Clariant manufacturing facility in Romorantin, ...
(Date:10/8/2015)... FRANCISCO , Oct. 8, 2015  Nektar Therapeutics ... the Company,s pain and oncology portfolio during an Investor ... - 3:30 p.m. Eastern Time in New ... carcinoma.  Details of the NKTR-214 Phase 1/2 clinical program ... CD122-biased immune-stimulatory cytokine designed to preferentially stimulate the production ...
(Date:10/8/2015)... -- Celtaxsys, a clinical stage drug development company focused on ... announced today the commencement of the US arm of ... compound, acebilustat, in patients with cystic fibrosis (CF). The ... the United States and European ... early 2016. This landmark clinical trial testing once-daily oral ...
Breaking Medicine Technology:
Cached News: